Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.
Data from Eiger BioPharmaceuticals, Inc.’s Phase III TOGETHER study of peginterferon lambda in non-hospitalized COVID-19 patients at high risk of progressing to severe disease or death showed the subcutaneous drug as highly effective in preventing hospitalization and death.
The company plans to speak with the US Food and Drug Administration and submit for emergency use authorization, as well...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
